CoChat
Sign Up
Cited by 9Extracellular vesicles in diseaseMesenchymal stem cell researchLiver physiology and pathology

Cutting-edge insights into liver fibrosis: advanced therapeutic strategies and future perspectives using engineered mesenchymal stem cell-derived exosomes

Open access
Didamoony, Manar A., Soubh, Ayman A., Ahmed, Lamiaa A.·2025·Drug Delivery and Translational Research
DOI 10.1007/s13346-024-01784-7PMC PMC12213925
Open this paper in CoChat — free accountOpen PDF

Abstract

Liver fibrosis is still a serious health concern worldwide, and there is increasing interest in mesenchymal stem cells (MSCs) with tremendous potential for treating this disease because of their regenerative and paracrine effects. Recently, many researches have focused on using the released exosomes (EXOs) from stem cells to treat liver fibrosis rather than using parent stem cells themselves. MSC-derived EXOs (MSC-EXOs) have demonstrated favourable outcomes similar to cell treatment in terms of regenerative, immunomodulatory, anti-apoptotic, anti-oxidant, anti-necroptotic, anti-inflammatory and anti-fibrotic actions in several models of liver fibrosis. EXOs are superior to their parent cells in several terms, including lower immunogenicity and risk of tumour formation. However, maintaining the stability and efficacy of EXOs after in vivo transplantation remains a major challenge in their clinical applicability. Therefore, several strategies have been applied in EXOs engineering, such as parental cell modification or modifying EXOs directly to achieve optimum performance of EXOs in treating liver fibrosis. Herein, we discuss the underlying mechanisms of liver fibrosis with an overview of the available therapies, among them EXOs. We also summarise the recent developments in improving the effectiveness of EXOs with the advantages and limitations of these approaches in terms of the upcoming clinical applications.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13346-024-01784-7

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Bioengineering or using biomaterials such as hydrogels to deliver EVs may be a potential improvement measure.

    “Bioengineering or using biomaterials such as hydrogels to deliver EVs may be a potential improvement measure [198, 259].”

    From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [198]

    The ‘Engineering approaches of EXOs > Cargo loading into EXOs’ section (page unavailable) says surface engineering can improve exosome targeting and therapeutic efficacy, supporting bioengineering as a potential improvement. It also describes a biomaterial used to modify exosome surfaces, but does not describe using hydrogels to deliver EVs; that specific example is unsupported. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 144

  1. [1]Nan Y, Su H, Lian X, Wu J, Liu S, Chen P, et al. Pathogenesis of liver fibrosis and its TCM therapeutic perspectives. Evid Based Complement Altern Med. 2022;(1):5325431. PMC9071861 35529927
  2. [2]Elbaset MA, Mohamed BMSA, Hessin A, Abd El-Rahman SS, Esatbeyoglu T, Afifi SM, et al. Nrf2/HO‐1, NF‐κB and PI3K/Akt signalling pathways decipher the therapeutic mechanism of pitavastatin in early phase liver fibrosis in rats. J Cell Mol Med. 2024;28:e18116. 38214394 PMC10844702 · DOI
  3. [3]El-Agroudy NN, El-Naga RN, El-Razeq RA, El-Demerdash E. Forskolin, a hedgehog signalling inhibitor, attenuates carbon tetrachloride-induced liver fibrosis in rats. Br J Pharmacol. 2016;173:3248–60. 27590029 PMC5071558 · DOI
  4. [4]Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells. 2020;9:1–43. PMC7226751 32260126 · DOI · Paper page
  5. [5]Didamoony MA, Atwa AM, Ahmed LA. Modulatory effect of rupatadine on mesenchymal stem cell-derived exosomes in hepatic fibrosis in rats: a potential role for miR-200a. Life Sci. 2023;324: 121710. 37084952 · DOI
  6. [6]Yang X, Wang Z, Kai J, Wang F, Jia Y, Wang S, et al. Curcumol attenuates liver sinusoidal endothelial cell angiogenesis via regulating Glis-PROX1-HIF-1α in liver fibrosis. Cell Prolif. 2020;53:e12762. 32119185 PMC7106966 · DOI
  7. [7]Ding Y, Luo Q, Que H, Wang N, Gong P, Gu J. Mesenchymal stem cell-derived exosomes: a promising therapeutic agent for the treatment of liver diseases. Int J Mol Sci. 2022;23:10972. 36142881 PMC9502508 · DOI
  8. [8]Gowen A, Shahjin F, Chand S, Odegaard KE, Yelamanchili SV. Mesenchymal stem cell-derived extracellular vesicles: challenges in clinical applications. Front cell Dev Biol. 2020;8:1–10. 32226787 PMC7080981 · DOI
  9. [9]Liu Q, Li S, Dupuy A, Le Mai H, Sailliet N, Logé C et al. Exosomes as new biomarkers and drug delivery tools for the Prevention and Treatment of various diseases: current perspectives. Int J Mol Sci. 2021;22(15):7763. PMC8346134 34360530
  10. [10]Didamoony MA, Soubh AA, Atwa AM, Ahmed LA. Innovative preconditioning strategies for improving the therapeutic efficacy of extracellular vesicles derived from mesenchymal stem cells in gastrointestinal diseases. Inflammopharmacology. 2023;1:1–21. PMC10692273 37874430
  11. [11]Rong X, Liu J, Yao X, Jiang T, Wang Y, Xie F. Human bone marrow mesenchymal stem cells-derived exosomes alleviate liver fibrosis through the Wnt/β-catenin pathway. Stem Cell Res Ther. 2019;10:1–11. 30885249 PMC6421647 · DOI
  12. [12]Wei W, Ao Q, Wang X, Cao Y, Liu Y, Zheng SG, et al. Mesenchymal stem cell-derived exosomes: a promising biological tool in nanomedicine. Front Pharmacol. 2021;11: 590470. 33716723 PMC7944140 · DOI
  13. [13]Lu Y, Mai Z, Cui L, Zhao X. Engineering exosomes and biomaterial-assisted exosomes as therapeutic carriers for bone regeneration. Stem Cell Res Ther. 2023;14:1–19. 36978165 PMC10053084 · DOI
  14. [14]Yin T, Liu Y, Ji W, Zhuang J, Chen X, Gong B, et al. Engineered mesenchymal stem cell-derived extracellular vesicles: a state-of-the-art multifunctional weapon against Alzheimer’s disease. Theranostics. 2023;13:1264–85. 36923533 PMC10008732 · DOI
  15. [15]Khanam A, Saleeb PG, Kottilil S. Pathophysiology and treatment options for hepatic fibrosis. Can It Be Completely Cured? Cells 2021. 2021;10:10:1097. 34064375 PMC8147843 · DOI
  16. [16]Matsuda M, Seki E. The liver fibrosis niche: novel insights into the interplay between fibrosis-composing mesenchymal cells, immune cells, endothelial cells, and extracellular matrix. Food Chem Toxicol. 2020;143:111556. 32640349 PMC7484466 · DOI
  17. [17]Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012;18:1028–40. 22772564 PMC3405917 · DOI · Paper page
  18. [18]Tsukada S, Parsons CJ, Rippe RA. Mechanisms of liver fibrosis. Clin Chim Acta. 2006;364:33–60. 16139830 · DOI
  19. [19]Sanchez-Valle V, Chavez-Tapia C, Uribe N, Mendez-Sanchez M. Role of oxidative stress and molecular changes in liver fibrosis: a review. Curr Med Chem. 2012;19:4850–60. 22709007 · DOI
  20. [20]Li S, Hong M, Tan H-Y, Wang N, Feng Y. Insights into the role and interdependence of oxidative stress and inflammation in liver diseases. Oxid Med Cell Longev. 2016;2016;4234061. PMC5192343 28070230
  21. [21]Yang JJ, Tao H, Hu W, Liu LP, Shi KH, Deng ZY, et al. MicroRNA-200a controls Nrf2 activation by target Keap1 in hepatic stellate cell proliferation and fibrosis. Cell Signal. 2014;26:2381–9. 25049078 · DOI
  22. [23]Didamoony MA, Atwa AM, Abd El-Haleim EA, Ahmed LA. Bromelain ameliorates D-galactosamine-induced acute liver injury: role of SIRT1/LKB1/AMPK, GSK3β/Nrf2 and NF-κB p65/TNF-α/caspase-8, -9 signalling pathways. J Pharm Pharmacol. 2022;74:1765–75. 36227279 · DOI
  23. [24]Zhao XJ, Yu HW, Yang YZ, Wu WY, Chen TY, Jia KK, et al. Polydatin prevents fructose-induced liver inflammation and lipid deposition through increasing miR-200a to regulate Keap1/Nrf2 pathway. Redox Biol. 2018;18:124–37. 30014902 PMC6068203 · DOI
  24. [25]Goodman ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol. 2007;47:598–607. 17692984 · DOI
  25. [26]Ganz M, Bukong TN, Csak T, Saha B, Park JK, Ambade A, et al. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice. J Transl Med. 2015;13:193. PMC4467677 26077675
  26. [27]Czaja AJ. Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World J Gastroenterol. 2014;20:2515–32. 24627588 PMC3949261 · DOI
  27. [28]Sharma N, Sistla R, Andugulapati SB. Yohimbine ameliorates liver inflammation and fibrosis by regulating oxidative stress and Wnt/β-catenin pathway. Phytomedicine. 2024;123: 155182. 37952411 · DOI
  28. [29]Dutta S, Chakraborty AK, Dey P, Kar P, Guha P, Sen S, et al. Amelioration of CCl4 induced liver injury in Swiss albino mice by antioxidant rich leaf extract of Croton bonplandianus Baill. PLoS ONE. 2018;13: e0196411. 29709010 PMC5927454 · DOI
  29. [30]Karantonis HC, Gribilas G, Stamoulis I, Giaginis C, Spiliopoulou C, Kouraklis G, et al. Platelet-activating factor involvement in thioacetamide-induced experimental liver fibrosis and cirrhosis. Dig Dis Sci. 2010;55:276–84. 19242794 · DOI
  30. [31]Borthakur A, Bhattacharyya S, Alrefai WA, Tobacman JK, Ramaswamy K, Dudeja PK. Platelet-activating factor-induced NF-κB activation and IL-8 production in intestinal epithelial cells are Bcl10-dependent. Inflamm Bowel Dis. 2010;16:593–603. 19714753 PMC3740729 · DOI
  31. [32]Dubois C, Bissonnette E, Rola-Pleszczynski M. Platelet-activating factor (PAF) enhances tumor necrosis factor production by alveolar macrophages. Prevention by PAF receptor antagonists and lipoxygenase inhibitors. J Immunol. 1989;143:964–70. 2545780 · DOI
  32. [33]Ruis NM, Rose JK, Valone FH. Tumor necrosis factor release by human monocytes stimulated with platelet-activating factor. Lipids. 1991;26:1060–4. 1668105 · DOI
  33. [34]Hassanein EHM, Ibrahim IM, Abd El-Maksoud MS, Abd El-Aziz MK, Abd-alhameed EK, Althagafy HS. Targeting necroptosis in fibrosis. Mol Biol Rep. 2023;50(12):10471–84. PMC10676318 37910384
  34. [35]Fulda S. Regulation of necroptosis signaling and cell death by reactive oxygen species. Biol Chem. 2016;397:657–60. 26918269 · DOI
  35. [36]Zhang X, Matsuda M, Yaegashi N, Nabe T, Kitatani K. Regulation of Necroptosis by phospholipids and sphingolipids. Cells. 2020;9:9. PMC7140401 32151027 · DOI
  36. [37]Zhang C, Dong H, Chen F, Wang Y, Ma J, Wang G. The HMGB1-RAGE/TLR-TNF-α signaling pathway may contribute to kidney injury induced by hypoxia. Exp Ther Med. 2019;17:17–26. 30651760 PMC6307518
  37. [38]Li LC, Gao J, Li J. Emerging role of HMGB1 in fibrotic diseases. J Cell Mol Med. 2014;18:2331–9. 25284457 PMC4302638 · DOI
  38. [39]Pang Q, Jin H, Wang Y, Dai M, Liu S, Tan Y, et al. Depletion of serotonin relieves concanavalin A-induced liver fibrosis in mice by inhibiting inflammation, oxidative stress, and TGF-β1/Smads signaling pathway. Toxicol Lett. 2021;340:123–32. 33429011 · DOI
  39. [40]Hu L, Lin X, Lu H, Chen B, Bai Y. An overview of hedgehog signaling in fibrosis. Mol Pharmacol. 2015;87:174–82. 25395043 · DOI
  40. [41]Omenetti A, Choi S, Michelotti G, Diehl AM. Hedgehog signaling in the liver. J Hepatol. 2011;54:366–73. 21093090 PMC3053023 · DOI
  41. [42]Chen J, Yang W, Dong T, Chen H, Zhang J, Xu G, et al. Quercetin ameliorates liver fibrosis in Wilson disease and EMT involving suppression of the hedgehog signaling pathway. Arab J Chem. 2024;17:105487.
  42. [43]Mansour SM, El-Abhar HS, Soubh AA. MiR-200a inversely correlates with hedgehog and TGF-β canonical/non-canonical trajectories to orchestrate the anti-fibrotic effect of Tadalafil in a bleomycin-induced pulmonary fibrosis model. Inflammopharmacology. 2021;29:167–82. 32914382 · DOI
  43. [44]Jiayuan S, Junyan Y, Xiangzhen W, Zuping L, Jian N, Baowei H, et al. Gant61 ameliorates CCl4-induced liver fibrosis by inhibition of hedgehog signaling activity. Toxicol Appl Pharmacol. 2020;387: 114853. 31816328 · DOI
  44. [45]Yang X, Ji W, Zhou Z, Wang J, Cui Z, Pan X, et al. Dendrobium officinale polysaccharide regulated hepatic stellate cells activation and liver fibrosis by inhibiting the SMO/Gli 1 pathway. J Funct Foods. 2024;112: 105960. · DOI
  45. [46]Kramann R. Hedgehog gli signalling in kidney fibrosis. Nephrol Dial Transpl. 2016;31:1989–95. 27229466 · DOI
  46. [47]Zadorozhna M, Di Gioia S, Conese M, Mangieri D. Neovascularization is a key feature of liver fibrosis progression: anti-angiogenesis as an innovative way of liver fibrosis treatment. Mol Biol Rep. 2020;47:2279–88. 32040707 · DOI
  47. [48]Melaibari M, Alkreathy HM, Esmat A, Rajeh NA, Shaik RA, Alghamdi AA, et al. Anti-fibrotic efficacy of apigenin in a mice Model of Carbon Tetrachloride-Induced hepatic fibrosis by modulation of oxidative stress, inflammation, and Fibrogenesis: a preclinical study. Biomedicines. 2023;11:11. PMC10216039 37239014 · DOI
  48. [49]Didamoony MA, Atwa AM, Ahmed LA. A novel mechanistic approach for the anti-fibrotic potential of rupatadine in rat liver via amendment of PAF/NF-ĸB p65/TGF-β1 and hedgehog/HIF-1α/VEGF trajectories. Inflammopharmacology. 2023;31:845–58. 36811777 PMC10140091 · DOI
  49. [50]Feng J, Wang C, Liu T, Li J, Wu L, Yu Q, et al. Procyanidin B2 inhibits the activation of hepatic stellate cells and angiogenesis via the hedgehog pathway during liver fibrosis. J Cell Mol Med. 2019;23:6479–93. 31328391 PMC6714206 · DOI
  50. [51]Liu Y, Zheng Y, Yang Y, Liu K, Wu J, Gao P, et al. Exosomes in liver fibrosis: the role of modulating hepatic stellate cells and immune cells, and prospects for clinical applications. Front Immunol. 2023;14:1–13. PMC10067730 37020547
  51. [52]Wang C, Liu J, Yan Y, Tan Y. Role of exosomes in chronic liver disease development and their potential clinical applications. J Immunol Res. 2022;2022:1695802. 35571570 PMC9106457
  52. [53]Gao J, Wei B, de Assuncao TM, Liu Z, Hu X, Ibrahim S, et al. Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis. J Hepatol. 2020;73:1144–54. 32389810 PMC7572579 · DOI · Paper page
  53. [54]Higashi T, Friedman SL, Hoshida Y. Hepatic stellate cells as key target in liver fibrosis. Adv Drug Deliv Rev. 2017;121:27–42. 28506744 PMC5682243 · DOI · Paper page
  54. [55]Chen L, Chen R, Kemper S, Charrier A, Brigstock DR. Suppression of fibrogenic signaling in hepatic stellate cells by Twist1-dependent microRNA-214 expression: role of exosomes in horizontal transfer of Twist1. Am J Physiol Gastrointest Liver Physiol. 2015;309:G491-499. 26229009 PMC4572411 · DOI
  55. [56]Wang R, Ding Q, Yaqoob U, De Assuncao TDM, Verma VK, Hirsova P, et al. Exosome adherence and internalization by hepatic stellate cells triggers sphingosine 1-Phosphate-dependent Migration. J Biol Chem. 2015;290:30684–96. 26534962 PMC4692200 · DOI
  56. [57]Chen L, Huang Y, Duan Z, Huang P, Yao H, Zhou Y, et al. Exosomal miR-500 derived from lipopolysaccharide-treated macrophage accelerates liver fibrosis by suppressing MFN2. Front cell Dev Biol. 2021;9:716209. PMC8525629 34676206
  57. [58]Chen L, Yao X, Yao H, Ji Q, Ding G, Liu X. Exosomal mir-103-3p from LPS-activated THP-1 macrophage contributes to the activation of hepatic stellate cells. FASEB J. 2020;34:5178–92. 32061112 · DOI
  58. [59]Peng Y, Li Z, Chen S, Zhou J. DHFR silence alleviated the development of liver fibrosis by affecting the crosstalk between hepatic stellate cells and macrophages. J Cell Mol Med. 2021;25:10049–60. 34626074 PMC8572769 · DOI
  59. [60]Wan L, Xia T, Du Y, Liu J, Xie Y, Zhang Y, et al. Exosomes from activated hepatic stellate cells contain GLUT1 and PKM2: a role for exosomes in metabolic switch of liver nonparenchymal cells. FASEB J. 2019;33:8530–42. 30970216 · DOI
  60. [62]Tanwar S, Rhodes F, Srivastava A, Trembling PM, Rosenberg WM. Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C. World J Gastroenterol. 2020;26:109–33. 31969775 PMC6962431 · DOI
  61. [64]Altamirano-Barrera A, Barranco-Fragoso B, Méndez-Sánchez N. Management strategies for liver fibrosis. Ann Hepatol. 2017;16:48–56. 28051792 · DOI
  62. [65]Lv K, Wang Y, Lou P, Liu S, Zhou P, Yang L, et al. Extracellular vesicles as advanced therapeutics for the resolution of organ fibrosis: current progress and future perspectives. Front Immunol. 2022;13:13. PMC9630482 36341339 · DOI
  63. [66]Tan Z, Sun H, Xue T, Gan C, Liu H, Xie Y, et al. Liver fibrosis: therapeutic targets and advances in Drug Therapy. Front Cell Dev Biol. 2021;9:2622. PMC8490799 34621747 · DOI
  64. [67]Liu P, Qian Y, Liu X, Zhu X, Zhang X, Lv Y, et al. Immunomodulatory role of mesenchymal stem cell therapy in liver fibrosis. Front Immunol. 2023;13: 1096402. 36685534 PMC9848585 · DOI
  65. [68]Musiał-Wysocka A, Kot M, Majka M. The pros and cons of mesenchymal stem cell-based therapies. Cell Transpl. 2019;28:801. PMC6719501 31018669 · DOI
  66. [69]Han C, Sun X, Liu L, Jiang H, Shen Y, Xu X et al. Exosomes and their therapeutic potentials of stem cells. Stem Cells Int. 2016;2016:7653489. PMC4684885 26770213
  67. [70]Rahimi B, Panahi M, Saraygord-Afshari N, Taheri N, Bilici M, Jafari D, et al. The secretome of mesenchymal stem cells and oxidative stress: challenges and opportunities in cell-free regenerative medicine. Mol Biol Rep. 2021;48:5607–19. 34191238 · DOI
  68. [71]Keshtkar S, Azarpira N, Ghahremani MH. Mesenchymal stem cell-derived extracellular vesicles: novel frontiers in regenerative medicine. Stem Cell Res Ther. 2018;9:1–9. 29523213 PMC5845209 · DOI
  69. [72]Ahmed L, Al-Massri K. New approaches for enhancement of the efficacy of mesenchymal stem cell-derived exosomes in cardiovascular diseases. Tissue Eng Regen Med. 2022;19(6):1129-1146. PMC9679101 35867309
  70. [73]Tian S, Zhou X, Zhang M, Cui L, Li B, Liu Y, et al. Mesenchymal stem cell-derived exosomes protect against liver fibrosis via delivering miR-148a to target KLF6/STAT3 pathway in macrophages. Stem Cell Res Ther. 2022;13(1):330. 35858897 PMC9297598 · DOI · Paper page
  71. [74]Chen W, Lin F, Feng X, Yao Q, Yu Y, Gao F et al. MSC-derived exosomes attenuate hepatic fibrosis in primary sclerosing cholangitis through inhibition of Th17 differentiation. Asian J Pharm Sci. 2024;19(1):100889. PMC10900800 38419761
  72. [75]Li T, Yan Y, Wang B, Qian H, Zhang X, Shen L, et al. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. Stem Cells Dev. 2013;22:845–54. 23002959 PMC3585469 · DOI
  73. [76]Ohara M, Ohnishi S, Hosono H, Yamamoto K, Yuyama K, Nakamura H, et al. xtracellular vesicles from amnion‐derived mesenchymal stem cells ameliorate hepatic inflammation and fibrosis in rats. Stem Cells International. 2018;(1):3212643. PMC6323530 30675167
  74. [77]Kim J, Lee C, Shin Y, Wang S, Han J, Kim M, et al. sEVs from tonsil-derived mesenchymal stromal cells alleviate activation of hepatic stellate cells and liver fibrosis through miR-486-5p. Mol Ther. 2021;29:1471–86. 33348053 PMC8058446 · DOI
  75. [78]Dong L, Pu Y, Chen X, Qi X, Zhang L, Xu L, et al. HUCMSC-extracellular vesicles downregulated hepatic stellate cell activation and reduced liver injury in S. japonicum-infected mice. Stem Cell Res Ther. 2020;11:1–11. 31918749 PMC6953150 · DOI
  76. [79]Tan Y, Huang Y, Mei R, Mao F, Yang D, Liu J, et al. HucMSC-derived exosomes delivered BECN1 induces ferroptosis of hepatic stellate cells via regulating the xCT/GPX4 axis. Cell Death Dis. 2022;13(4):1–11. PMC8993870 35395830 · DOI
  77. [80]Wang S, Guo L, Ge J, Yu L, Cai T, Tian R, et al. Excess integrins cause lung entrapment of mesenchymal stem cells. Stem Cells. 2015;33:3315–26. 26148841 · DOI
  78. [81]Jeong JO, Han JW, Kim JM, Cho HJ, Park C, Lee N, et al. Malignant tumor formation after transplantation of short-term cultured bone marrow mesenchymal stem cells in experimental myocardial infarction and Diabetic Neuropathy. Circ Res. 2011;108:1340–7. 21493893 PMC3109741 · DOI
  79. [82]Badillo AT, Beggs KJ, Javazon EH, Tebbets JC, Flake AW. Murine bone marrow stromal progenitor cells elicit an in vivo Cellular and Humoral Alloimmune Response. Biol Blood Marrow Transpl. 2007;13:412–22. PMC1892590 17382248 · DOI
  80. [83]Madrigal M, Rao KS, Riordan NH. A review of therapeutic effects of mesenchymal stem cell secretions and induction of secretory modification by different culture methods. J Transl Med. 2014;12:260. PMC4197270 25304688
  81. [84]Chen S, Sun F, Qian H, Xu W, Jiang J. Preconditioning and Engineering Strategies for Improving the Efficacy of Mesenchymal Stem Cell‐Derived Exosomes in Cell‐Free Therapy. Stem cells international. 2022;(1):1779346. PMC9124131 35607400
  82. [85]Zhang W, Liu R, Chen Y, Wang M, Du J. Crosstalk between Oxidative Stress and Exosomes. Oxid Med Cell Longev. 2022;3553617. PMC9448575 36082080
  83. [86]Wang J, Wu H, Peng Y, Zhao Y, Qin Y, Zhang Y, et al. Hypoxia adipose stem cell-derived exosomes promote high-quality healing of diabetic wound involves activation of PI3K/Akt pathways. J Nanobiotechnol. 2021;19:19. PMC8261989 34233694
  84. [87]Liu W, zhao, Ma Z, Li Jru, Kang X. Mesenchymal stem cell-derived exosomes: therapeutic opportunities and challenges for spinal cord injury. Stem Cell Res Ther. 2021;12(1):102. 33536064 PMC7860030 · DOI · Paper page
  85. [88]Zhu L, Sun HT, Wang S, Huang SL, Zheng Y, Wang CQ, et al. Isolation and characterization of exosomes for cancer research. J Hematol Oncol. 2020;13:1-24. PMC7652679 33168028
  86. [89]Cheng L, Zhang K, Wu S, Cui M, Xu T. Focus on mesenchymal stem cell‐derived exosomes: opportunities and challenges in cell‐free therapy. Stem cells international. 2017;(1):6305295. PMC5749272 29410682
  87. [90]Zhang Z, Dombroski JA, King MR. Engineering of exosomes to target cancer metastasis. Cell Mol Bioeng. 2020;13:1. 32030104 PMC6981329 · DOI
  88. [91]Wang J, Bonacquisti EE, Brown AD, Nguyen J. Boosting the Biogenesis and Secretion of Mesenchymal Stem Cell-Derived exosomes. Cells. 2020;9. PMC7140620 32182815
  89. [92]Antimisiaris SG, Mourtas S, Marazioti A. Exosomes and exosome-inspired vesicles for targeted drug delivery. Pharmaceutics. 2018;10. 30404188 PMC6321407 · DOI
  90. [93]Noronha Nc NDC, Mizukami A, Caliári-Oliveira C, Cominal JG, Rocha JLM, Covas DT et al. Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies. Stem Cell Res Ther. 2019;10(1):131. PMC6498654 31046833
  91. [94]Lou G, Yang Y, Liu F, Ye B, Chen Z, Zheng M, et al. MiR-122 modification enhances the therapeutic efficacy of adipose tissue-derived mesenchymal stem cells against liver fibrosis. J Cell Mol Med. 2017;21:2963–73. 28544786 PMC5661245 · DOI
  92. [95]Qu Y, Zhang Q, Cai X, Li F, Ma Z, Xu M, et al. Exosomes derived from mir-181-5p-modified adipose-derived mesenchymal stem cells prevent liver fibrosis via autophagy activation. J Cell Mol Med. 2017;21:2491–502. 28382720 PMC5618698 · DOI
  93. [96]Wang J, Ye W, Jiang M, Zhou Y, Zheng J. Therapeutic potential of exosome derived from hepatocyte growth factor-overexpressing adipose mesenchymal stem cells in TGFβ1-stimulated hepatic stellate cells. Cytotechnology. 2024;76:217–29. 38495297 PMC10940570 · DOI
  94. [97]Xu AL, Han L, Yan J, Liu D, Wang W. Effects of mesenchymal stem cells-derived Extracellular vesicles on inhibition of hepatic fibrosis by delivering miR-200a. Tissue Eng Regen Med. 2024;21:609–24. 38568409 PMC11087440 · DOI
  95. [98]Cao Y, Yang H, Huang Y, Lu J, Du H, Wang B. Mesenchymal stem cell-derived exosomal miR-26a induces ferroptosis, suppresses hepatic stellate cell activation, and ameliorates liver fibrosis by modulating SLC7A11. Open Med (Warsaw, Poland). 2024;19:20240945. PMC11097046 38756248
  96. [99]Fiore E, Domínguez LM, Bayo J, Malvicini M, Atorrasagasti C, Rodriguez M, et al. Human umbilical cord perivascular cells-derived extracellular vesicles mediate the transfer of IGF-I to the liver and ameliorate hepatic fibrogenesis in mice. Gene Ther. 2020;27:62–73. 31551525 · DOI
  97. [102]Haney MJ, Klyachko NL, Zhao Y, Gupta R, Plotnikova EG, He Z, et al. Exosomes as drug delivery vehicles for Parkinson’s disease therapy. J Control Release. 2015;207:18–30. 25836593 PMC4430381 · DOI · Paper page
  98. [103]Walker S, Busatto S, Pham A, Tian M, Suh A, Carson K, et al. Extracellular vesicle-based drug delivery systems for cancer treatment. Theranostics. 2019;9:8001–17. 31754377 PMC6857056 · DOI
  99. [104]Woo CH, Kim HK, Jung GY, Jung YJ, Lee KS, Yun YE, et al. Small extracellular vesicles from human adipose-derived stem cells attenuate cartilage degeneration. J Extracell Vesicles. 2020;9(1):1735249. PMC7144299 32284824
  100. [105]Liang L, Zhao L, Wang Y, Wang Y. Treatment for hepatocellular carcinoma is enhanced when Norcantharidin is encapsulated in Exosomes derived from bone marrow mesenchymal stem cells. Mol Pharm. 2021;18:1003–13. 33527831 · DOI
  101. [106]Xing H, Liang C, Xu X, Sun H, Ma X, Jiang Z. Mesenchymal stroma/stem-like cells of GARP knockdown inhibits cell proliferation and invasion of mouse colon cancer cells (MC38) through exosomes. J Cell Mol Med. 2020;24:13984–90. 33155413 PMC7753840 · DOI
  102. [107]Gomari H, Moghadam MF, Soleimani M, Ghavami M, Khodashenas S. Targeted delivery of doxorubicin to HER2 positive tumor models. Int J Nanomed. 2019;14:5679–90. PMC6662522 31413568 · DOI
  103. [109]Guo S, Perets N, Betzer O, Ben-Shaul S, Sheinin A, Michaelevski I, et al. Intranasal delivery of mesenchymal stem cell derived exosomes loaded with phosphatase and tensin homolog siRNA repairs complete spinal cord Injury. ACS Nano. 2019;13:10015–28. 31454225 · DOI · Paper page
  104. [110]Tang M, Chen Y, Li B, Sugimoto H, Yang S, Yang C et al. Therapeutic targeting of STAT3 with small interference RNAs and antisense oligonucleotides embedded exosomes in liver fibrosis. FASEB J. 2021;35(5):e21557. PMC10851328 33855751
  105. [111]Tang M, Guo C, Sun M, Zhou H, Peng X, Dai J, et al. Effective delivery of osteopontin small interference RNA using exosomes suppresses liver fibrosis via TGF-β1 signaling. Front Pharmacol. 2022;13:13. PMC9478741 36120332
  106. [112]Zhou W, Zhou Y, Chen X, Ning T, Chen H, Guo Q et al. Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment. Biomaterials. 2021;268:120546. 33253966
  107. [113]Greco KA, Franzen CA, Foreman KE, Flanigan RC, Kuo PC, Gupta GN. PLK-1 Silencing in Bladder Cancer by siRNA delivered with exosomes. Urology. 2016;91:241.e1-241.e7. 26876462 · DOI
  108. [114]Shojaei S, Hashemi SM, Ghanbarian H, Salehi M, Mohammadi-Yeganeh S. Effect of mesenchymal stem cells-derived exosomes on tumor microenvironment: tumor progression versus tumor suppression. J Cell Physiol. 2019;234:3394–409. 30362503 · DOI
  109. [115]Azizsoltani A, Hatami B, Zali MR, Mahdavi V, Baghaei K, Alizadeh E. Obeticholic acid-loaded exosomes attenuate liver fibrosis through dual targeting of the FXR signaling pathway and ECM remodeling. Biomed Pharmacother. 2023;168: 115777. 37913732 · DOI · Paper page
  110. [116]Fang J, Liang W. ASCs -derived exosomes loaded with vitamin A and quercetin inhibit rapid senescence-like response after acute liver injury. Biochem Biophys Res Commun. 2021;572:125–30. 34364291 · DOI · Paper page
  111. [118]Zhai Z, Cui T, Chen J, Mao X, Zhang T. Advancements in engineered mesenchymal stem cell exosomes for chronic lung disease treatment. J Transl Med. 2023;21(1):895. PMC10709966 38071321
  112. [119]Xu M, Feng T, Liu B, Qiu F, Xu Y, Zhao Y, et al. Engineered exosomes: desirable target-tracking characteristics for cerebrovascular and neurodegenerative disease therapies. Theranostics. 2021;11:8926–44. 34522219 PMC8419041 · DOI · Paper page
  113. [120]Mentkowski KI, Snitzer JD, Rusnak S, Lang JK. Therapeutic potential of engineered extracellular vesicles. AAPS J. 2018;20:50. 29546642 PMC8299397 · DOI
  114. [121]Villata S, Canta M, Cauda V. EVs and bioengineering: from cellular products to Engineered Nanomachines. Int J Mol Sci. 2020;21:1–32. PMC7504061 32842627 · DOI
  115. [122]Salunkhe S, Dheeraj, Basak M, Chitkara D, Mittal A. Surface functionalization of exosomes for target-specific delivery and in vivo imaging & tracking: strategies and significance. J Control Release. 2020;326:599–614. 32730952
  116. [123]Lin Y, Yan M, Bai Z, Xie Y, Ren L, Wei J, et al. Huc-MSC-derived exosomes modified with the targeting peptide of aHSCs for liver fibrosis therapy. J Nanobiotechnol. 2022;20:20. PMC9526331 36183106 · DOI · Paper page
  117. [124]Hung ME, Leonard JN. Stabilization of exosome-targeting peptides via engineered glycosylation. J Biol Chem. 2015;290:8166–72. 25657008 PMC4375473 · DOI
  118. [125]Tamura R, Uemoto S, Tabata Y. Augmented liver targeting of exosomes by surface modification with cationized pullulan. Acta Biomater. 2017;57:274–84. 28483695 · DOI
  119. [126]Kooijmans SAA, Fliervoet LAL, Van Der Meel R, Fens MHAM, Heijnen HFG, Van Bergen En Henegouwen PMP, et al. PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time. J Control Release. 2016;224:77–85. 26773767 · DOI
  120. [127]Hwang DW, Jo MJ, Lee JH, Kang H, Bao K, Hu S et al. Chemical modulation of bioengineered exosomes for tissue-specific Biodistribution. Adv Ther. 2019;2(11):1900111. PMC7172497 32318623
  121. [128]Nakase I, Noguchi K, Aoki A, Takatani-Nakase T, Fujii I, Futaki S. Arginine-rich cell-penetrating peptide-modified extracellular vesicles for active macropinocytosis induction and efficient intracellular delivery. Sci Rep. 2017;7:7. 28512335 PMC5434003 · DOI
  122. [129]Zheng L, Gong H, Zhang J, Guo L, Zhai Z, Xia S et al. Strategies to improve the therapeutic efficacy of mesenchymal stem cell-derived extracellular vesicle (MSC-EV): a promising cell-free therapy for liver disease. Front Bioeng Biotechnol. 2023;11:1322514. PMC10753838 38155924
  123. [130]Qu Q, Fu B, Long Y, Liu Z-Y, Tian X-H. Current strategies for promoting the large-scale production of Exosomes. Curr Neuropharmacol. 2023;21:1964–79. 36797614 PMC10514529 · DOI
  124. [131]Gómez-Ferrer M, Villanueva-Badenas E, Sánchez-Sánchez R, Sánchez-López CM, Baquero MC, Sepúlveda P et al. HIF-1α and pro-inflammatory signaling improves the Immunomodulatory activity of MSC-Derived Extracellular vesicles. Int J Mol Sci. 2021;22(7):3416. PMC8036951 33810359
  125. [132]Hassan MNF, Bin, Yazid MD, Yunus MHM, Chowdhury SR, Lokanathan Y, Idrus RBH, et al. Large‐scale expansion of human mesenchymal stem cells. Stem Cells International. 2020;(1):9529465. PMC7378617 32733574
  126. [133]Yan L, Wu X. Exosomes produced from 3D cultures of umbilical cord mesenchymal stem cells in a hollow-fiber bioreactor show improved osteochondral regeneration activity. Cell Biol Toxicol. 2020;36:165–78. 31820164 PMC7196084 · DOI
  127. [134]Wang N, Li X, Zhong Z, Qiu Y, Liu S, Wu H, et al. 3D hESC exosomes enriched with mir-6766-3p ameliorates liver fibrosis by attenuating activated stellate cells through targeting the TGFβRII-SMADS pathway. J Nanobiotechnol. 2021;19:19. PMC8686281 34930304 · DOI
  128. [135]Xiong Y, Tang R, Xu J, Jiang W, Gong Z, Zhang L et al. Sequential transplantation of exosomes and mesenchymal stem cells pretreated with a combination of hypoxia and Tongxinluo efficiently facilitates cardiac repair. Stem Cell Res Ther. 2022;13(1):63. PMC8822662 35130979
  129. [136]Wei X, Zheng W, Tian P, Liu H, He Y, Peng M, et al. Administration of glycyrrhetinic acid reinforces therapeutic effects of mesenchymal stem cell-derived exosome against acute liver ischemia-reperfusion injury. J Cell Mol Med. 2020;24:11211–20. 32902129 PMC7576231 · DOI
  130. [137]Kharaziha P, Hellström PM, Noorinayer B, Farzaneh F, Aghajani K, Jafari F, et al. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur J Gastroenterol Hepatol. 2009;21:1199–205. 19455046 · DOI · Paper page
  131. [138]Liang J, Zhang H, Zhao C, Wang D, Ma X, Zhao S, et al. Effects of allogeneic mesenchymal stem cell transplantation in the treatment of liver cirrhosis caused by autoimmune diseases. Int J Rheum Dis. 2017;20:1219–26. 28217916 · DOI · Paper page
  132. [139]Vosough M, Moossavi S, Mardpour S, Akhlaghpoor S, Azimian V, Jarughi N, et al. Repeated intraportal Injection of mesenchymal stem cells in combination with pioglitazone in patients with compensated cirrhosis: a clinical report of two cases. Arch Iran Med. 2016;19:131–6. 26838084
  133. [140]Lotfy A, AboQuella NM, Wang H. Mesenchymal stromal/stem cell (MSC)-derived exosomes in clinical trials. Stem Cell Res Ther. 2023;14:1–18. 37024925 PMC10079493 · DOI · Paper page
  134. [141]Kordelas L, Rebmann V, Ludwig AK, Radtke S, Ruesing J, Doeppner TR, et al. MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia. 2014;28:970–3. 24445866 · DOI
  135. [142]Nassar W, El-Ansary M, Sabry D, Mostafa MA, Fayad T, Kotb E, et al. Umbilical cord mesenchymal stem cells derived extracellular vesicles can safely ameliorate the progression of chronic kidney diseases. Biomater Res. 2016;20:20. 27499886 PMC4974791 · DOI
  136. [143]Kwon HH, Yang SH, Lee J, Park BC, Park KY, Jung JY, et al. Combination treatment with human adipose tissue stem cell-derived exosomes and fractional CO2 laser for Acne scars: a 12-week prospective, Double-blind, Randomized, Split-face study. Acta Derm Venereol. 2020;100:1–8. PMC9309822 33073298 · DOI
  137. [144]Sengupta V, Sengupta S, Lazo A, Woods P, Nolan A, Bremer N. Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19. Stem Cells Dev. 2020;29:747–54. 32380908 PMC7310206 · DOI
  138. [145]Xu Y, Zhou X, Wang X, Jin Y, Zhou L, Ye J. Progress of mesenchymal stem cells (MSCs) & MSC-Exosomes combined with drugs intervention in liver fibrosis. Biomed Pharmacother. 2024;176:116848. 38834005
  139. [146]Sun Y, Liu G, Zhang K, Cao Q, Liu T, Li J. Mesenchymal stem cells-derived exosomes for drug delivery. Stem Cell Res Ther. 2021;12:12. 34717769 PMC8557580 · DOI
  140. [147]Liu A, Lin D, Zhao H, Chen L, Cai B, Lin K, et al. Optimized BMSC-derived osteoinductive exosomes immobilized in hierarchical scaffold via lyophilization for bone repair through Bmpr2/Acvr2b competitive receptor-activated smad pathway. Biomaterials. 2021;272:120467. 33838528
  141. [148]Driscoll J, Yan IK, Patel T. Development of a Lyophilized off-the-shelf mesenchymal stem cell-derived Acellular therapeutic. Pharmaceutics. 2022;14(4):849. PMC9030800 35456683 · DOI
  142. [149]Guo Y, Zhai Y, Wu L, Wang Y, Wu P, Xiong L. Mesenchymal stem cell-derived extracellular vesicles: pleiotropic impacts on breast Cancer occurrence, Development, and Therapy. Int J Mol Sci. 2022;23(6):2927. PMC8954385 35328347
  143. [150]Harrell CR, Jankovic MG, Fellabaum C, Volarevic A, Djonov V, Arsenijevic A, et al. Molecular mechanisms responsible for anti-inflammatory and immunosuppressive effects of mesenchymal stem cell-derived factors. Adv Exp Med Biol. 2019;1084:187–206. 31175638 · DOI
  144. [152]Benten D, Kluwe J, Wirth JW, Thiele ND, Follenzi A, Bhargava KK, et al. A humanized mouse model of liver fibrosis following expansion of transplanted hepatic stellate cells. Lab Invest. 2018;98:525–36. 29352225 PMC6526950 · DOI

Cited by

Sorted by citations

Authors
Didamoony, M. A., Soubh, A. A., & Ahmed, L. A.
Affiliations
  • Egyptian Russian University (EG)
  • Ahram Canadian University (EG)
  • Cairo University (EG)
Corresponding author
  • Didamoony, Manar A.
  • Ahmed, Lamiaa A.
ORCID
Venue
Drug Delivery and Translational Research
Publisher
Springer Science and Business Media LLC
Published
2025-01-24
Volume
15
Issue
8
Pages
2608-2623
ISSN
  • 2190-393X (ISSN-L)
  • 2190-3948
DOI
10.1007/s13346-024-01784-7
PMC
PMC12213925
OpenAlex
W4406801113
Cited by
9
References
7
Citations by year
2026: 3 · 2025: 6
FWCI
0.80
Type
journal article
Language
en
Open access
Licence
Locations
  • Drug Delivery and Translational Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Cairo University
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
liver fibrosis, mesenchymal stem cells, exosomes, exosome engineering, stem cell-derived exosomes, exosome stability, immunomodulation, anti-inflammatory activity, antifibrotic therapy, regenerative therapy, clinical translation
MeSH terms
Animals, Humans, Liver Cirrhosis, Mesenchymal Stem Cell Transplantation, Exosomes, Mesenchymal Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review